Anthropic unveils Claude Science, an AI workbench for scientists that unifies research databases, computing power, and coding tools to accelerate healthcare research and drug discovery.

The platform leverages agent-ready tools built on NVIDIA BioNeMo, NIM microservices, Parabricks, NeMo, and Nemotron, enabling agents to gather evidence, reason, run experiments, and propose next steps.

More than 50 organizations use BioNeMo for workflows such as protein structure prediction, molecular docking, generative chemistry, genomic analysis, protein design, and biomarker discovery, with notable collaborations including Arc Institute and University of Washington’s Institute for Protein Design.

Early tests show stronger agent behavior with Sonnet 5, though some developers question real running costs due to tokenizer changes and higher token consumption.

Limitations include a tokenizer that may raise costs for certain workloads and cybersecurity capabilities that don’t match the top tier for high-security tasks, with a slightly higher misalignment risk guiding task-specific model choice.

For IT leaders, Sonnet 5 shifts focus from raw benchmarks to practical business value, deployment costs, security, governance, and integration.

FAQ clarifies that Sonnet 5 emphasizes agentic capabilities with reliability and safety, is the default for free/Pro plans, and offers introductory pricing through late August, with safety improvements yet not foolproof against misaligned behavior.

Anthropic’s ongoing IPO process adds strategic weight to Sonnet 5 in the market narrative, signaling how the company may scale while some models remain offline.

The release follows conversations about AI shrinkflation around earlier models and aims to counter perceived declines with Sonnet 5.

Sonnet 5 targets budget-conscious businesses amid rising token costs, aligning with industry trends of reducing AI spend.

Big tech buyers like Meta, Amazon, and Uber trimming AI tool spending create demand for cost-efficient models like Sonnet 5.

The launch occurs in a broader push to curb token usage and control costs across the industry.